---
title: "TD Cowen Keeps Their Buy Rating on Soleno Therapeutics (SLNO)"
description: "Van Buren covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Regeneron, and Gilead Sciences. According to TipRanks, Van Buren has an average return of 3.9% and a 48.86% succ"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260046030.md"
published_at: "2025-10-06T11:36:02.000Z"
---

# TD Cowen Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

> Van Buren covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Regeneron, and Gilead Sciences. According to TipRanks, Van Buren has an average return of 3.9% and a 48.86% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Soleno Therapeutics with a $119.30 average price target, a 101.49% upside from current levels. In a report released on October 3, Piper Sandler also maintained a Buy rating on the stock with a $145.00 price target.

Van Buren covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Regeneron, and Gilead Sciences. According to TipRanks, Van Buren has an average return of 3.9% and a 48.86% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Soleno Therapeutics with a $119.30 average price target, a 101.49% upside from current levels. In a report released on October 3, Piper Sandler also maintained a Buy rating on the stock with a $145.00 price target.

### Related Stocks

- [SLNO.US - Soleno Therapeutics](https://longbridge.com/en/quote/SLNO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Stifel Nicolaus Remains a Buy on Soleno Therapeutics (SLNO) | According to TipRanks, Condulis is a 2-star analyst with an average return of 5.6% and a 61.54% success rate. Condulis c | [Link](https://longbridge.com/en/news/258743068.md) |
| LifeSci Capital Sticks to Their Buy Rating for Soleno Therapeutics (SLNO) | Currently, the analyst consensus on Soleno Therapeutics is a Strong Buy with an average price target of $117.36. | [Link](https://longbridge.com/en/news/264449481.md) |
| A Look At Acadia Healthcare (ACHC) Valuation After David Einhorn Stake And Leadership Changes | Acadia Healthcare (ACHC) gained attention after David Einhorn disclosed a new stake, leading to increased trading volume | [Link](https://longbridge.com/en/news/275994576.md) |
| Where Were The Job Opportunities In 2025? Where Will They Be In 2026? | In 2025, job growth was minimal, with only Education and Health Care (+697,000 jobs) and Leisure and Hospitality (+119,0 | [Link](https://longbridge.com/en/news/275986113.md) |
| Jefferies Reaffirms Their Hold Rating on Novartis AG (NOVN) | Jefferies analyst James Vane has reaffirmed a Hold rating on Novartis AG (NOVN) with a price target of CHF110.00. Vane,  | [Link](https://longbridge.com/en/news/276102881.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
